Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

First Independent U.s. Psoriasis Registry Will Track Drug Safety And Effectiveness -- Portland, Ore., Feb. 26, 2015 /prnewswire-usnewswire/ --

Healthiest Foods of All Time (With Recipes)

healthiest foods, health food, diet, nutrition, time.com stock, red wine, alcohol About the National Psoriasis Foundation National Psoriasis Foundation (NPF) is the world's largest nonprofit serving those with psoriasis and psoriatic arthritis. Our priority is to provide the services people need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our education and advocacy initiatives, NPF has funded more than $10 million in psoriatic disease research grants and fellowships. Learn more at www.psoriasis.org or call 800.723.9166. Follow us on Facebook and Twitter . About Corrona, LLC Corrona, LLC was founded in 2000 by leading rheumatologists dedicated to advancing and improving the care of patients with rheumatic and other chronic diseases. Corrona's mission is to advance medical research and improve the quality of patient care.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/first-independent-us-psoriasis-registry-will-track-drug-safety-and-effectiveness-300041765.html

Research and Markets: Chronic Plaque Psoriasis Pipeline Review 2015 - Analysis of 20 Companies & 22 Drug Profiles - Yahoo Finance

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development AbGenomics International, Inc.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/research-markets-chronic-plaque-psoriasis-121800165.html

Is This Amgen's Next Big Thing? (AMGN)

State law currently allows residents 18 or older to register as medical marijuana patients if they have any of the following conditions: cancer, glaucoma, HIV or AIDS, Parkinson's disease, multiple sclerosis, intractable spasticity related to nerve damage in the spinal cord, epilepsy, cachexia, wasting syndrome, Crohn's disease or post-traumatic stress disorder. This is the second wave of petitions to expand the medical marijuana program. Several other conditions could be added soon: sickle cell disease; severe psoriasis and psoriatic arthritis; and post-laminectomy syndrome with chronic radiculopathy recurring back pain after surgery. Petitioners asked for those conditions to be added. The state medical marijuana program's board of physicians reviewed them and recommended they be added to the list of existing conditions. The board of physicians declined to add Tourette syndrome. The marijuana program is part of the state Department of Consumer Protection, overseen by Commissioner Jonathan A.
For the original version including any supplementary images or video, visit http://www.courant.com/business/hc-medical-marijuana-connecticut-colitis-20150302-story.html?track=rss

Cellceutix to Expand Its Skin Product Pipeline - Yahoo Finance

In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix will soon begin a Phase 2 clinical trial with its people with psoriasis novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's uvb psoriasis treatment lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cellceutix-expand-skin-product-pipeline-143141096.html

Petitioners Ask To Add 3 Ailments To Medical Marijuana Program - Hartford Courant

Also at risk are its top-selling autoimmune drug Enbrel and the anemia drug Epogen. Enbrel lost patent protection in Europe this year, and Epogen has already lost patent protection in the U.S. and Europe.
For the original version including any supplementary images or video, visit http://www.investopedia.com/articles/markets/030215/amgens-next-big-thing.asp?partner=mediafed

Remove vegetable mixture from pan, and keep warm. Sprinkle chicken with remaining 1 1/2 teaspoons chopped rosemary, remaining 1 teaspoon thyme, remaining 1/4 teaspoon salt, and remaining 1/4 teaspoon pepper. Add chicken and olives to pan. Bake at 425 for 35 minutes or until chicken is done. Garnish with rosemary sprigs, if desired.
For the original version including any supplementary images or video, visit http://time.com/3724505/50-healthiest-foods/

3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year - NASDAQ.com

Over time, Pharmacyclics believes that Imbruvica's addressable patient population across blood cancers could climb from 40,000 people today to more than 374,000. If that happens, then Pharmacyclics EPS should climb nicely over the coming years from the adjusted net income of $1.80 reported in 2014. For example, the average analyst expects that Pharmacyclics' EPS will more than double from current levels, to hit $3.94 in 2016. If so, that would mean that its growth trounces that of Gilead Sciences from here. Tying it together Gilead Sciences has a market-leading HIV and hepatitis C franchise, and its expansion into oncology shows that it deserves a spot in investor portfolios. However, the faster growth of Celgene, Biogen Idec, and Pharmacyclics could mean that their shares that prove to be more profit friendly to investors this year. This coming blockbuster will make every biotech jealous The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else.
For the original version including any supplementary images or video, visit http://www.nasdaq.com/article/3-big-cap-biotechs-that-could-trounce-gilead-sciences-this-year-cm449603

Don't be the product, buy the product!